It is generally accepted that inhibition of nitric oxide synthase (NOS) facilitates, and thus nitric oxide (NO) inhibits, contractility of skeletal muscle. However, standard assessments of contractility are carried out at a nonphysiological oxygen tension [partial pressure of oxygen (pO2)] that can interfere with NO signaling (95% O2). We therefore examined, in normal and neuronal NOS (nNOS)-deficient mice, the influence of pO2 on whole-muscle contractility and on myocyte calcium flux and sarcomere shortening. Here, we demonstrate a significant enhancement of these measures of muscle performance at low physiological pO2 and an inhibitory influence at higher physiological pO2, which depend on endogenous nNOS. At 95% O2 (which produces oxidative stress; muscle core pO2 Ϸ400 mmHg), force production is enhanced but control of contractility by NO͞nitrosylation is greatly attenuated. In addition, responsivity to pO2 is altered significantly in nNOS mutant muscle. These results reveal a fundamental role for the concerted action of NO and O2 in physiological regulation of skeletal muscle contractility, and suggest novel molecular aspects of myopathic disease. They suggest further that the role of NO in some cellular systems may require reexamination.
It has recently been recognized that redox-based regulation of protein function serves not only to mediate compensatory responses to oxidative or nitrosative stress but also modulates transduction along basic signaling pathways in mammalian cells (1). Further, accumulating evidence indicates that nitric oxide (NO)-based protein modifications are critical effectors of redox regulation, which may be linked at the molecular level to partial pressure of oxygen (pO 2 ) (1). Accordingly, the functional contribution of redox mechanisms remains, for the most part, untested, and potentially masked in virtually all ex vivo studies, which have been carried out at supranormal oxygen tension (typically 21% O 2 for cells and 95% O 2 for tissue, whereas pO 2 in vivo is much lower).Mammalian skeletal muscle operates over a range of pO 2 , which is determined by local blood flow and muscle activity, and contains endogenous sources of NO. The -isoform of type I or neuronal NO synthase (nNOS) localizes to the plasma membrane (sarcolemma) of skeletal muscle fibers through interaction with the dystrophin complex (2-4). In many mammals, nNOS is either restricted to or particularly abundant in fast-twitch fibers, although, in humans, fast-and slow-twitch fibers are more evenly endowed (2, 5, 6). The loss of nNOS from sarcolemma of mdx mice (whose fast-twitch fibers are disproportionately impaired), and of patients with Duchenne or Becker muscular dystrophy, focused interest on the possibility that NO produced by muscle fibers may play a role in excitation-contraction (E-C) coupling and that NO deficiency may contribute to contractile impairment in muscle disease (2-6). However, although mice deficient in nNOS show subtle abnormalities in muscle blood flow (7), overt alterations in contractile fun...